Studies on the Local Administration of 2,3,5-Tri-Ethylene-Imino-1,4-Benzoquinone (Trenimon) to Epitheliomas**From the Department of Dermatology, Ros-well Park Memorial Institute, Buffalo 3, New York.  by Helm, Frederick et al.
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Copyright C 1565 by The Williams & Wilkins Co.
STUDIES ON THE LOCAL ADMINISTRATION OF
2,3, 5-TRI-ETHYLENE-IMINO- 1, 4-BENZOQUINONE
(TRENIMON) TO EPITHELIOMAS*
vol. 45, No. T
Printed in U.S.A..
FREDERICK HELM, M.D., EDMUND KLEIN, M.D., HERBERT L.
TRAENKLE, M.D. AND EUGENE P. RIVERA, M.D.t
some value in the treatment of lymphomas. Like
most cytostatic agents, it is less effective against
solid tumors, hut has been used orally and in-
travenously in metastatic breast and ovarian
cancer. Detailed data on those numerous obser-
vations are available in the published proceed-
ings of several symposia on the chemotherapy of
cancer (11, 15, 16).
Trenimon has been administered locally in
patients With malignant cutaneous tumors.
Spiessl (1) reported dramatic results with in-
tralesional injections of tumors of the maxilla
and face. Likewise, Pillat (2, 3) and Siebeck
(4) have reported favorable results in treating
basal cell carcinoma of the eyelids with intra-
tumoral injections of a structurally related
agent (Bayer E 39). Poschko (5) applied a
0.2% Trenimon solution to areas of mycosis
fungoides in a patient who was also receiving
intravenous injections of the drug. Belisario (17,
18) reported on single courses of topical adminis-
tration of Trenimon to basal cell carcinoma; he
observed resolution of tumors accompanied by
a marked inflammatory response without ap-
parent sensitization.
In this report, observations on the action of
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METHOD5 AND MATERTAL5
Methods of administration—a) Inunction of
0.05% Trenimon in Eucerin (W/O emulsion) ap-
plied with or without occlusive dressing.
b) Intratumoral injection of 0.1—0.5 ml of a so-
lution of 0.1% Trenimon in physiologic saline pre-
pared immediately prior to administration. The
amount iniected was adjusted to approximate a
ratio of 0.1 cc per cm1 of lesion.
The ointment was applied at least every other
day to the tumor and to a surrounding margin (5
mm in width) of apparently normal skin under oc-
clusive dressing. Macerated and necrotic tissue was
gently removed with gauze before reapplication of
the ointment. Following the onset of erosion, the
ointment was applied without occlusive dressing.
The frequency and duration of application were
guided by the reaction of the tumor and the sur-
rounding skin as well as by the depth of the tumor
as suggested by pre-treatment biopsy examination.
Selection of lesions.—123 epitheliomas in twelve
patients were selected (Table I). These included 94
lesions in one patient with superficial epithelioma-
tosis.
Clinical observations were accompanied by mi-
croscopic examination prior to, during, and follow-
ing the course of Trenimon administration. In the
presence of multiple epitheliomas n number of
representative, randomly selected lesions were re-
moved for biopsy study.
Systemic toxicity—Complete blood counts and
urinalysis were carried out at weekly intervals;
total protein determinations and paper electro-
phoresis of plasma proteins were performed at the
beginning and at the end of the study. No abnor-
malities were observed except a mild leukocytosis
in patients who developed a contact dermatitis.
Investigotion of irritating or sensitizing pro p-
erties of drug.—Occlusive (24 hours) patch
tests with 0.05% Trenimon in Eucerin were
carried out on healthy volunteers and in pa-
tients with epitheliomas, at the beginning and
after termination of an initial Trenimon appli-
cation. When the initial patch tests with 0.05%
Trenimon gave positive results, further patch
tests were performed subsequently with the
152
locally administered Trenimon to basal and
squamous cell carcinoma are presented.
Trenimon (2,3,5-Tri-cthylcne-imino-1 ,4-
benzoquinone) was developed following studies
of the closely related compound Bayer E 39
(2, 5-Bis-n-propoxy-3 , 6-bis ethylene imino-l ,4-
benzoquinonc). Trenimon exerts direct action
on tissues and does not require conversion or
decomposition in the body to become cytostati-
cally effective. It has been given orally, intra-
venously, as well as locally, by intra-tumoral,
intra-pleural, and intra-peritoncal injections.
When given systemically, Trenimon has been
found to be effective in polycythemia and has
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TABLE I
Lesions Duration Sensi-
Diagnosis
.
ties- Remarks
No. Diameter or iojertisn tion
1. superficial epithel- 94 3-17 7 days; after + 1 excisional biop. revealed nests of
iomatosis sensitiza- basal cell carcinoma in the deep
tion: 5 hours corium. Complete regression of
the other lesions.
2. arsenicepithelioma 5 4—39 17 days Complete regression. Results sup-
perior to concurrent x-ray and co-
agulation of comparable lesions.
3. superficial basal 7 4—12 7 days + Discontinued because of severe irri-
cell carcinoma tation. Regression of all lesions.
Second course of Trenimon caused
generalized exfoliative dermatitis.
4. multiple basal cell 2 4&5 10 days + Complete regression.
carcinomas
5. basal cell carci- 1 12 3 injections at + Intratumoral injection followed by
noma (nodular, two week in- severe local reaction, contra-indi-
nose) tervals (to- eating further injections. Incom-
tal amount 5 plete regression.
mg.)
6. arsenic epithelioma 2 6&9 14 days + Complete regression of tumors. Tem-
porary clearing of psoriatic lesion.
7. basal cell nevus 2 3&4 3 days No regression.
syndrome
8. pigmented basal 2 3&7 14 days + Discontinued due to irritation. Com-
cell carcinomas plete regression of tumor.
9. (a) squamous cell 1 13 13 days + Incomplete regression of squamous
carcinoma cell ca. Allergic contact dermatitis
(b) solar keratoses >30 3—S 13 days + develop, on 13th day over entire
face. Erosions appeared in areas of
keratoses on both sides of the face;
(Trenimon had been applied to
left side of face only.)
10. recurrent basal 1 3 21 days + Trenimon discontinued on 21st day
cell carcinoma due to severe irritation. Complete
regression.
11. squamous cell car- 2 6&13 28 days No regression.
cinomas
12. multiple keratoses >15 3-5 34 days + Resolutiont of keratoses; 2 of 4 re-
& squamous cell biopsies revealed residual squa-
carcinoma in mous cell carcinoma. In spite of
areas of chronic sensitization appearing on 24th
radiodermatitis 4 day, continuous application of
Trenimon was possible by adding
5% hydrocortisone to the oint-
ment.
* Sensitization was not manifest within the first 15 days of treatment.
t Regression refers to no evidence of tumor on excisional biopsy or, where excisions of all treated
areas was not possible, following gross and microscopic studies for observation periods up to 15 months.
A number of lesions recurred following apparently complete resolution, within 2—6 months. Other
keratoses, which had undergone resolution, have not recurred within an observation period of 12 months.
154 THE JOUENAL OF INVESTIGATIVE DERMATOLOGY
Eucerin base alone and with other test substances
in order to rule out a polyvalent hypersensitivity.
The initial 24 hour patch test result with
0.05% Trenimon in Eucerin was positive in
only 1 of 30 individuals prior to the adminis-
tration of the drug as an anti-tumor agent.
This patient had a generalized eczematous erup-
tion associated with multiple (polyvalent) sen-
sitivities as demonstrated by positive patch
tests to several potentially sensitizing agents.
None of the 12 patients who had Trenimon
administered locally as an anti-tumor agent
for at least 15 days became sensitized to it
during that period. Within 6 weeks, however,
9 patients had become sensitized to Trenimon
as indicated by the results of repeated patch
tests.
Clinical observations regarding anti-tumor ef-
feet—Clinical changes due to continuous apph-
cation of Trenimon ointment in non-sensitized
patients usually appeared in the second week.
These consisted of slight erythema and edema,
seen first at the site of the tumors which became
raised and succulent. Three to four weeks of ap-
plication were usually necessary to produce
erosions and ulcerations at the tumor sites. The
surrounding skin showed a variable degree of
erythema. Sensitization appeared most fre-
quently in the 3rd and 4th week.
Application of Trenimon to sensitized pa-
tients caused, after a latent period of 6—24
hours, erythema and edema, most marked at
the site of the tumors. The epitheliomas became
elevated and sharply delineated, while at this
time the surrounding skin was only slightly
erythematous. The development of pin-point
vesicles was followed by oozing and crusting.
Papulovesieular lesions also appeared distant to
the site of application. Erosions and necrosis
preceded the eventual onset of ulcerations. The
eroded areas were larger than the clinically
apparent extent of the tumors. Occlusive dress-
ings accelerated and enhanced the manifesta-
tions associated with Trenimon application.
Complete re-epitbelialization was apparent
within 1—8 weeks of terminating the administra-
tion of Trenimon. The time required for healing
depended on the size and depth of the tumor
and the duration of the application of Trcnimon.
The resulting scars were fine and smooth.
With 4 exceptions, some degree of involu-
tion took place in all epithcliomas to which
the drug had been topically applied. The lesions
which did not react to Trenimon were tw&
basal cell epitheliomas to which the drug had
been applied for only 3 days, and two squamous
cell carcinomas which did not show extensive
changes after 28 daily applications.
Clinical appearance following intratumor in—
jection.—Intratumoral injection at 2 week in-
tervals was attempted on a basal cell carcinoma
of the ala nasi (Fig. 1). The first two injections,
(2 mg Trenimon dissolved in physiologic saline)
were quite painful. Within approximately S
hours after injection, crythema, edema and in-
filtration extending into the surrounding skin
were noted. Within a week, necrosis and marked
decrease in tumor size became apparent. The
third injection (0.5 mg of Trenimon) had less
effect on the tumor, but caused a severe reaction
including marked edema, which contra-indi-
cated further injections. Despite the marked
reaction, the tumor did not completely regress
(Fig. 2).
Intradermal injection as controls .—Intrader-
mal injections of 0.15 mg Trenimon dissolved
in 0.05 cc of physiologic saline into normal
skin of non-sensitized volunteers caused ne-
crosis within 2—7 days. The resulting ulcers
(Fig. 3) healed very slowly and were followed
by an atrophic scar which microscopically re-
sembled some of the changes seen in chronic
radiodcrmatitis.
Histological observations.—After topical appli-
cation of Trenimon ointment to the skin of non-
sensitized patients, a round cell infiltrate consisting
of lymphocytes and a few plasma cells was seen.
In some areas of the normal epidermis, vacuoliza-
tion of cells and an increase in the number and
size of coarse irregular kerato-hyalin granules were
noted (Fig. 4).
In areas involved by squamous cell carcinoma,
gigantic tumor cells with irregularly shaped nuclei
and homogeneous cytoplasm appeared (Fig. 5).
These cells were similar to those seen after radia-
tion treatment of squamous cell carcinomas. Ne-
crosis and ulceration of tumor were evident during
prolonged administration.
After healing, adnexal structures were absent;
the rete ridges were flattened and the upper and
middle layer of the corium appeared to have un-
dergone hyalinization. These changes were most
marked following intradermal injection. Hyalini-
zation of the connective tissue, fibrotic thickening
of the walls of blood vessels leading to obliterative
changes, and the appearance of enlarged, hyper-
chromatic fibroblasts closely resembled the changes
seen in late radiodcrmatitis (Fig. 6).
In the sensitized patients, application of Trcni-
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FIG. 1. Basal cell carcinoma of nose prior to Trenimon administration
FIG. 2. Basal cell carcinoma, after three intra-tumoral injections of Trenimon
FIG. 3. Punched out ulcer 3 months after intracutaneous Trenimon injection (3 X)
mon produced contact dermatitis with marked
spongiosis, exocytosis and erosions (Fig. 7). These
changes were not specific for the reaction to Treni-
mon and were consistent with those seen in any
acute dermatitis (6).
Although 14 pre-treatment biopsy specimens,
taken from a patient with multiple lesions, showed
basal cell carcinomas superficially located in all
sections, one of the excisional follow-up specimens
(Fig. 8) revealed nests of tumor cells in the lower
eorium. While the tumor may originally have been
at this level, the pre-treatment specimens did not
indicate this location. Therefore, residual tumor
may have become submerged during sear forma-
tion. Sullivan (7) reported this phenomenon in his
studies on the action of podophyllin as an anti-
tumor agent.
DISCUSSION
Ehrig (5) reported Bayer E 39 (2,5-Bis-n-
propoxy - (3,6) Bis - ethylene - imino - 1,4 -ben -
.
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Fie. 4. Epidermis after 2 weeks of topical Trenimon application. Vacuolization and an
increase of coarse, irregular keratohyaline granules is apparent (328 X).
FJG. 5. Gigantic tumor cell of squamous cell carcinoma with irregular shaped nucleus and
homogenous eosinophilic cytoplasma (328 X).
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FIG. 6 (top). Hyalinization of the connective tissue and fibrotic thickening of the blood
vessels leading to narrowing of the lumen (164 X).
Fic. 7 (bottom). On the right side, in an area of acanthosis, a spongiotic vesicle, exocytosis
and an inflammatory infiltrate are seen. On the left there is an edge of an ulcer crater with
a nest of residual basal cell carcinoma at its base (164 X).
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Fm. 8. Nests of basal cell carcinoma in the lower corium following clinical regression
after Trenimon application (82 X).
zoquinone), a related imino-benzoquinone coiji-
pound, to be relatively ineffective on topical
application to squamous and basal cell carci-
nomas. Repeated intra-tumoral injections of the
same agent, however, caused pronounced in-
flammation and partial necrosis of the tumor.
This action was not selective for neoplastic
cells, and a large number of the carcinomas
recurred. Ehrig therefore concluded that the
effects of E 39 seemed to be more irritating
than cytostatic. Gros, Keiling and Le Gal (9)
failed to demonstrate clinical or histological
evidence for a cytostatic action of E 39 on
epitheliomas. These observations differ from
those of Pillat (2, 3) and Siebeek (4) who re-
ported regressions of basal cell carcinomas in-
cluding particularly lesions of the eyelids, fol-
lowing local injection of E 39 in over 100
patients. Knaus (10) reported that intra-tumoral
injection of Trenimon produced regression of
carcinomas of the cervix. Further exploration of
the anti-tumor effects of Trenimon has been
reported from several centers (11—13).
Although sensitization to alkylating agents is
known to occur and has been described and
discussed by Sulzberger et al. (14), to our
knowledge it has not been reported after
topical application of Trenimon. In our studies
on Trenimon, we were able to demonstrate by
initial 24 hour patch testing that Trenimon at
a concentration of 0.05% is not a primary
irritant. Application under occlusive dressing
for at least 5 days was necessary to produce
irritation.
There was a marked difference in the action
of Trenimon ointment on the normal skin and
on skin tumors. Trenimon caused erosions at
the site of the tumor at a time when the sur-
rounding skin showed only slight erythema. It
is noteworthy that the tumors did not regress
until some degree of necrosis developed. This
destructive phenomenon appeared to be essen-
tial for the gross and microscopic elimination
of neoplastie tissue.
The observations reported here have dealt
with destruction of neoplastic lesions, rather
than with simple regression or inhibition of
growth. Effects on the blood vessels in particu-
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lar and on connective tissue in general seemed
to follow prolonged application. This would
further suggest that the action of Trenimon is
not primarily associated with direct inhibition
of mitotie activity, hut is exerted through its
action on the supporting structures of the neo-
plastic lesion. In respect to this action of the
agent, there is some resemblance to effects of
ionizing radiation.
CONCLUSIONS
Trenimon, a compound of the ethylene-imino
benzoquinone group, when locally administered,
appeared to exert a selective destructive effect
against small superficial basal and squamous cell
epitheliomas.
In non-sensitized patients, local application
for 14—21 days was required for the eradication
of superficial tumors.
Following sensitization, eradication of super-
ficial basal cell lesions in a patient with super-
ficial epitheliomatosis was effected by 1 to 3
applications of the drug.
Trenimon is a potentially sensitizing agent, but
in the concentration used this compound can
also exert a primary irritant effect on prolonged
application under an occlusive dressing.
In some post-treatment biopsy specimens, the
histologic changes resembled those seen in late
radiodermatitis.
The clinical evaluation of local chemotherapy
of skin carcinoma may be misleading as demon-
strated by buried islands of residual tumor cells
after apparent clinical cure. Hence, such agents
are not yet suitable for routine therapeutic use.
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